Proteomic Analysis of Waldenstrom Macroglobulinemia

Harvard University, Cambridge, Massachusetts, United States
Cancer Research (Impact Factor: 9.33). 05/2007; 67(8):3777-84. DOI: 10.1158/0008-5472.CAN-06-3089
Source: PubMed


To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKalpha. Other proteins up-regulated by >1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by >2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics.

Download full-text


Available from: Steven Treon
  • Source
    • "Antibody Microarray 500 (Clontech, Mountain View, CA) was used to profile relative expression levels of 507 proteins. The Clontech antibody array has been used in a variety of settings since 2003 (Anderson et al., 2003; Hatjiharissi et al., 2007). Independent publications report high validity of differential protein expression, verified with Western blotting, and our preliminary study findings were consistent with this. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although neuritic plaques and neurofibrillary tangles in older adults are correlated with cognitive impairment and severity of dementia, it has long been recognized that the relationship is imperfect, as some people exhibit normal cognition despite high levels of Alzheimer's disease (AD) pathology. We compared the cellular, synaptic, and biochemical composition of midfrontal cortices in female subjects from the Religious Orders Study who were stratified into three subgroups: (1) pathological AD with normal cognition ("AD-Resilient"), (2) pathological AD with AD-typical dementia ("AD-Dementia"), and (3) pathologically normal with normal cognition ("Normal Comparison"). The AD-Resilient group exhibited preserved densities of synaptophysin-labeled presynaptic terminals and synaptopodin-labeled dendritic spines compared with the AD-Dementia group, and increased densities of glial fibrillary acidic protein astrocytes compared with both the AD-Dementia and Normal Comparison groups. Further, in a discovery-type antibody microarray protein analysis, we identified a number of candidate protein abnormalities that were associated with a particular diagnostic group. These data characterize cellular and synaptic features and identify novel biochemical targets that may be associated with resilient cognitive brain aging in the setting of pathological AD.
    Full-text · Article · May 2012 · Neurobiology of aging
  • Source
    • "Preclinical data have been demonstrated that monoclonal gammopaties are characterized by disregulation of several signalling pathways, as compared to normal plasma cells (Hideshima et al 2004a; Hatjiharissi et al 2007; Leleu et al 2007). Moreover there is strong evidence that BM-milieu supports the growth of the clonal cell population. "
    [Show abstract] [Hide abstract]
    ABSTRACT: THE PARADIGM FOR THE TREATMENT OF MONOCLONAL GAMMOPATIES HAS DRAMATICALLY CHANGED: therapeutic options in multiple myeloma (MM) have evolved from the introduction of melphalan and prednisone in the 1960s, high-dose chemotherapy and stem cell transplantation in the late 1980s and 1990s, to the rapid introduction of small novel molecules within the last seven years. Based on the understanding of the complex interaction of the MM cells with the bone marrow microenvironment and the signaling pathways that are dysregulated in this process, a number of novel therapeutic agents are now available. Specifically, three novel agents with a specific-targeted anti-MM activity, have been FDA-approved for the treatment of this disease, namely Bortezomib, thalidomide, and lenalidomide which are now all playing a key role in the treatment of MM. The success of targeted therapy in MM has since led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenström's macroglobulinemia and primary amyloidosis, both in the preclinical settings and as part of clinical trials.
    Full-text · Article · Oct 2008 · Targets & therapy
  • Source

    Preview · Article · Feb 1984 · Revista Clínica Española
Show more